Search or
𝛼SK
𝛼SKbullish
Innovent Biologics Placement - Second for the Month, Stock Has Doubled but Momentum Is Strong
514 Views25 Jun 2025 18:12
Innovent Biologics Inc (1801 HK) aims to raise around US$500m for R&D and marketing. In this note, we talk about the deal dynamics.
What is covered in the Full Insight:
- Introduction to Innovent Biologics
- Previous Placements and Stock Performance
- Current Deal Dynamics
- Aequitas Momentum-Adjusted Deal Stag Framework Analysis
- Conclusion and Recommendations
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Ascentage Pharma Top-Up Placement - Past Deals Didn't Done Well, Stock up a Lot but Sector Is Strong14 Jul 2025
- Innovent Biologics Placement - Momentum Is Very Strong but past Deals Have Been Mixed14 Jan 2021
- Innovent Biologics (信达生物) Placement - Back on the Market but This Time with Secondary Selldown22 Jul 2020
x